Kinito

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kinito

Quick Facts

Property Description
Active ingredient Itopride hydrochloride
Form Oral film-coated tablet
Pharmacological class Gastroprokinetic agent
General purpose Relieving symptoms of digestive sluggishness
Origin Synthetic substituted benzamide

Classification and Composition

Kinito is a prescription-only medicine with the core active substance being Itopride hydrochloride. The drug is formally classified as a gastroprokinetic agent. This synthetic compound is structurally categorized as a substituted benzamide derivative. Its pharmacological identity is defined by a unique dual mechanism: it functions by simultaneously acting as a dopamine D₂ receptor antagonist and an acetylcholinesterase inhibitor.

The efficacy of Itopride’s dual mechanism is clinically recognized for providing a comprehensive approach to motility regulation. This prokinetic is often noted for its predominantly peripheral action, focusing its effects on the gut wall, which is a key differentiating factor. Kinito is intended for oral administration and is supplied in the form of a film-coated tablet, a single-ingredient product designed for systematic delivery within the digestive system.

General Purpose of the Prokinetic Action

The overall function of Kinito is to address discomfort caused by poor coordination, or dysmotility, in the upper digestive system. By enhancing muscle contractions in the stomach and small intestine, Kinito facilitates more effective gastric emptying, which is the primary therapeutic aim. This mechanical correction is how the medicine generally helps relieve common, disruptive symptoms such as persistent feelings of post-meal fullness (early satiety), uncomfortable bloating, and prolonged upper abdominal distress. The therapeutic benefit centers on restoring the digestive tract's efficient transit capacity, a foundational requirement for managing functional digestive discomfort.

What side effects are possible with Kinito?

Possible Side Effects and Safety Information

The officially documented adverse effects of Kinito (Itopride hydrochloride) are classified based on the regulatory frequency framework and System-Organ Class (SOC) categories established by government health authorities.

Adverse reactions reported in clinical data are primarily categorized as Uncommon, meaning they affect up to 1 in 100 people. These include gastrointestinal disorders such as diarrhea, constipation, and abdominal pain, along with nervous system disorders like headache and dizziness. Changes in laboratory tests, such as elevated creatinine and Leucopenia (low white cell count), are also classified as Uncommon.

Less frequently, events are classified as Rare (up to 1 in 1,000 people), primarily encompassing skin and subcutaneous tissue disorders like rash and itching.

Certain adverse reactions, including Thrombocytopenia (low platelet count), Jaundice, Tremor, and Anaphylactoid Reaction (a serious, acute allergic-like response), have been reported in post-marketing surveillance and are classified as Not Known frequency (incidence cannot be estimated from available data).

Serious Adverse Reactions documented in the safety profile include the potential for Liver Dysfunction (Jaundice) and Anaphylactoid Reactions. The label notes that if hormonal effects, such as Hyperprolactinaemia or Gynecomastia (male breast enlargement), are observed, treatment interruption or termination may be necessary.

Safety Restrictions and Special Populations

Kinito is contraindicated when increased gastrointestinal motility could be harmful, such as in cases of gastrointestinal hemorrhage, mechanical obstruction, or perforation. Caution is advised when prescribing the medicine to older adults due to the higher likelihood of reduced organ function. Furthermore, the safety and efficacy of the active substance have not been established in children under the age of 16 years.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding an overdose of Kinito (Itopride hydrochloride) is derived exclusively from regulatory documents and established clinical principles. Understanding the official profile is essential for recognizing when emergency actions are required.

Documented Overdose Profile

Regulatory labeling states that there is currently no experience with overdose in humans that has been formally reported. As a result, no specific or unique clinical signs, symptoms, or physiological findings are officially documented in the prescribing information as being definitively associated with an overdose event. This lack of specific data means that any potential overdosage must be treated with caution.

Emergency Actions Mandated by Regulation

In the case of suspected or excessive overdosage, immediate contact with emergency medical services is required. Management is strictly defined as supportive. Regulatory documents confirm that no specific antidote for Itopride is known. Therefore, the intervention strategy must focus on general emergency procedures and observation. The officially mandated supportive measures include the application of the usual management techniques, such as gastric lavage, alongside the initiation of comprehensive symptomatic therapy. This protocol emphasizes that any situation involving excessive intake necessitates urgent medical evaluation and intervention for monitoring and supportive care, as officially described in government prescribing information.

Therapeutic Uses of Kinito

Therapeutic Indications

Kinito is a prokinetic medication primarily indicated for the treatment of gastrointestinal symptoms associated with functional dyspepsia and chronic gastritis. It is used to manage physical discomfort arising from impaired gastric motility, which can slow the movement of food through the digestive tract.

Main Uses

The medication is used to address a complex of symptoms in the upper digestive tract, including:

  • Postprandial fullness: A sensation of the stomach remaining uncomfortably full for an extended period after eating.
  • Upper abdominal bloating: Physical swelling or a feeling of pressure in the epigastric region.
  • Early satiety: Feeling full shortly after beginning a meal, preventing the consumption of a normal-sized portion.
  • Epigastric pain or discomfort: General aching or localized distress in the upper abdomen.
  • Heartburn and nausea: Secondary symptoms often associated with delayed gastric emptying.

Mechanism of Action and Benefits

Kinito works by enhancing the natural contractions of the stomach and small intestine. By facilitating more efficient movement of gastric contents into the duodenum, it helps restore a more regular digestive rhythm.

Expected Clinical Benefits

  • Improved Gastric Emptying: The primary benefit is the reduction of the time food spends in the stomach, which directly alleviates the sensation of heaviness and bloating.
  • Symptom Relief: Clinical use focuses on reducing the frequency and intensity of chronic dyspeptic symptoms that interfere with daily nutritional intake and comfort.
  • Enhanced Motility: It supports the coordination of the digestive muscles without affecting the secretion of gastric acid, making it a targeted option for motility-related disorders.

Regulatory References

  1. EMA therapeutic overview

Eligibility and Restrictions for Use

Kinito is officially designated for use in adult patients (18 years and older). Regulatory documents define strict population eligibility criteria centered on absolute contraindications and conditional use requirements.

The medicine is contraindicated in patients with a known hypersensitivity to Itopride hydrochloride or any of its excipients. Absolute prohibition also extends to patients with specific acute gastrointestinal conditions, including established haemorrhage, mechanical obstruction, or perforation, as increasing gut motility in these circumstances could be harmful.

Use is not recommended for children and adolescents because the safety and efficacy of the active substance have not been established in these younger age groups. Similarly, the medicine is not recommended for pregnant or breastfeeding women, unless a physician determines that the potential therapeutic benefits significantly outweigh the possible risks.

For certain populations, use is conditional and requires close monitoring. Elderly patients and those with reduced hepatic or renal function must be carefully monitored, with regulatory guidelines stating that therapy may need to be discontinued or the dosage reduced if adverse reactions occur. Furthermore, patients with rare metabolic disorders, such as galactose intolerance, should not take Kinito due to its excipient content.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Kinito (Cinitapride) has documented pharmacodynamic interactions with several categories of medicines, primarily due to its effects on the central nervous system and vascular tone. These interactions can increase the risk of specific adverse effects or decrease the intended therapeutic activity of co-administered drugs.

Interacting Product Category Potential Effect and Mechanism
CNS Depressants (e.g., Opioids, Benzodiazepines, certain Antidepressants) Increased risk or severity of Central Nervous System depression due to additive depressant effects.
Antihypertensives (e.g., Beta-blockers, ACE Inhibitors, Calcium Channel Blockers) Decreased antihypertensive activities; Kinito may oppose the blood pressure-lowering effect.
Serotonin-acting agents (e.g., Triptans, SSRIs) Increased risk or severity of Serotonin Syndrome due to combined serotonergic activity.
NSAIDs and other pressor agents Increased risk or severity of hypertension (high blood pressure).

Restrictions and Notes: Concomitant use with drugs that are CNS depressants, Serotonin-acting agents, or Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may require close clinical monitoring to manage the potentially increased severity of side effects. Kinito's prokinetic action on the digestive tract may also reduce the absorption and efficacy of some oral medicines, such as Digoxin. Caution is advised when combining Kinito with any medication that affects heart rhythm.

Mechanism of Action

Kinito (Itopride) functions through a dual pharmacodynamic mechanism that modulates the muscle contractility of the upper digestive tract. The drug operates almost exclusively within the enteric nervous system (ENS), the intrinsic neural network of the gut wall.

Dual Modulation of GI Neurotransmitters

This action involves two distinct molecular targets: Kinito acts as an antagonist on Dopamine D2 receptors while simultaneously serving as an inhibitor of the enzyme Acetylcholinesterase (AChE). This complementary dual action contributes to the modulation of nerve impulses that influence gut motility.

The Pro-Motility Cholinergic Cascade

This domain explains the resulting pathway effect: by blocking the inhibitory D2 receptor, Kinito promotes the release of Acetylcholine (ACh), the key excitatory neurotransmitter for gut movement. Furthermore, by inhibiting AChE, the drug prevents the rapid breakdown of ACh, prolonging the binding and action of ACh to the smooth muscle cells. The resulting physiological change is the acceleration of gastric emptying and the promotion of organized peristaltic coordination.

Dosage and Administration Information

Kinito is administered solely via the oral route as a 50 mg film-coated tablet. The standard adult regimen involves taking a single 50 mg dose three times daily (TID), resulting in a total daily dose of 150 mg. For correct use, the tablet must be swallowed whole with water and consistently taken before meals (preprandial timing).

Treatment with Kinito is typically limited to a short course, with a maximum duration in clinical studies being eight weeks. If a dose is missed, the patient should take the next scheduled dose at the usual time and not double the dose to compensate.

Administration rules require specific caution for certain patient groups. Individuals with moderate or severe hepatic or renal impairment require careful monitoring and may necessitate a dose reduction or discontinuation due to altered drug metabolism. Similarly, due to potential physiological changes, older adults must be managed with adequate caution, and dosing may be adjusted based on clinical status. Use in children and adolescents under 16 years of age is not established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kinito

Evidence for Use in Functional Dyspepsia (FD)

The research base for Kinito has primarily examined the compound in adult patients with Functional Dyspepsia (FD), a condition studied for symptoms such as gastric discomfort and digestive sluggishness. The core evidence consists primarily of short-term (4- to 8-week) randomized controlled trials (RCTs). These studies were designed to compare Kinito against an inactive substance (placebo) or sometimes against an active comparator, observing how symptoms evolved over a defined period. Research explored how symptoms evolved in the observed populations, particularly for individuals experiencing postprandial fullness (feeling full too quickly) and bloating.

Researchers monitored several key outcomes related to physical discomfort and functional imbalance. These included how patients rated their experience using a Global Patient Assessment (GPA) and measurements of the Gastric Emptying Rate. Findings describe patterns observed in these measurements. However, findings across all research have been mixed. While some meta-analyses synthesizing the data described patterns observed in the active treatment group, results across individual, large, high-quality RCTs were not always consistent. This shows that evidence quality varies across studies, and certainty regarding consistent outcomes appears low in some trial populations.


Long-Term Research and Evidence Gaps

The short-term RCTs provide the most controlled data on observations made during the initial period. Some patients continued into open-label extension studies for longer periods, sometimes up to six months to one year. These observational settings are primarily used to monitor patients over time. Long-term outcomes regarding symptom patterns over many months are not fully established by the same high-certainty research used for the initial 8-week period.

Furthermore, data for certain groups remain insufficient. For instance, there is limited information available specifically detailing Kinito research in the pediatric population. Studies focusing exclusively on older adults with multiple co-existing health conditions also appear limited. Overall, comparative evidence against newer treatments is often lacking, and research exploring short-term symptom changes does not determine whether an individual will respond similarly.

Key Studies & References

  1. EMA Therapeutic Overview and Prescribing Information for Medicinal Products Containing Itopride (SKL Document)

Frequently Asked Questions (FAQ)

Common questions about Kinito (FAQ)


Q: How quickly can someone expect to feel the effects of Kinito?

A: Studies on Kinito indicate that the drug is absorbed rapidly and extensively following oral intake. Peak concentrations in the blood are generally observed around 35 minutes following a dose.


Q: How long does one dose of Kinito stay in your system?

A: According to official pharmacokinetic data, Kinito has an elimination half-life of approximately six hours. This value indicates the average time required for half of the medication to be eliminated from the body.


Q: Will Kinito interact with common over-the-counter pain relievers?

A: The official product information advises caution when combining Kinito with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), a category that includes some common over-the-counter pain relievers. This combination has been associated with an increased potential for high blood pressure (hypertension).


Q: Are there any specific supplements or vitamins that should be avoided while taking Kinito?

A: Kinito’s action to speed up movement in the digestive system may reduce how well the body absorbs and uses some oral medicines and supplements. Regulatory caution is advised when taking any oral supplement, especially those known to influence heart rhythm.


Q: Can people taking Kinito consume alcohol, and if so, how much is considered safe?

A: Kinito is associated with potential enhanced Central Nervous System (CNS) effects when combined with CNS depressants. Official labeling generally recommends minimizing or limiting alcohol intake due to the potential for enhanced central nervous system (CNS) effects.


Q: How long is Kinito usually prescribed for?

A: Kinito treatment is generally intended for a short course. Clinical studies that established its use were typically limited to a maximum duration of eight weeks.


Q: Can Kinito be taken on an empty stomach, or must it be with food?

A: The official instructions for Kinito specify that the tablets should be taken before meals (preprandial timing).


Q: What foods or juices should definitely not be consumed with Kinito?

A: Official guidance for the condition Kinito treats may recommend avoiding certain dietary irritants, such as excessive coffee. Grapefruit juice consumption has also been associated with an increased likelihood of unwanted effects.


Q: Does Kinito affect the effectiveness of birth control pills?

A: Kinito's prokinetic (motility-enhancing) action in the digestive tract may potentially reduce the absorption of some oral medicines, which includes some oral contraceptives. The potential interaction should be reviewed by a healthcare provider.


Q: Where can I find reliable, non-biased information about Kinito studies?

A: Information on government-regulated clinical trials is available on public databases such as the U.S. National Institutes of Health’s ClinicalTrials.gov.


Q: Are there any routine tests or monitoring needed while on Kinito?

A: Because Kinito has been associated with changes in lab results, such as low white blood cell counts (Leucopenia) and liver enzyme increases, these parameters may require monitoring.


Q: What are the most commonly reported side effects people mention online for Kinito?

A: Official reports classify side effects like headache, dizziness, diarrhea, and abdominal pain as Uncommon, affecting up to 1 in 100 people. Official frequency data is the basis for regulatory information, not anecdotal reports from online forums.


Q: Is it normal to feel a bit light-headed when first starting Kinito?

A: Feeling light-headedness or dizziness is a possible adverse effect of Kinito. Official documentation classifies dizziness as an Uncommon side effect.


Q: Does Kinito cause drowsiness or affect energy levels?

A: Official product information reports that some individuals may experience sleep disorders, such as insomnia. Other sources suggest the possibility of drowsiness. Caution is advised for activities requiring full alertness.


Q: Are there any warnings about using Kinito while breastfeeding?

A: Kinito is generally not recommended for use while breastfeeding. The official reason is that the medicine may be excreted in breast milk, and the potential effects on the infant are not fully established.


Q: Why would a doctor choose Kinito over an older, more established medicine?

A: Kinito is characterized by a unique dual mechanism of action—it blocks a dopamine receptor and inhibits a neurotransmitter-breaking enzyme. Its action is predominantly concentrated in the digestive system, which contrasts with the properties of some older prokinetic medications.


Q: Do generic versions of Kinito work just as well as the brand name?

A: Regulatory authorities require that generic versions demonstrate bioequivalence to the original branded product. This means that a generic version is expected to provide the same clinical effect and safety profile as the brand-name product.


Q: Is Kinito safe to use during pregnancy, based on general guidance?

A: The official position is that Kinito is generally not recommended during pregnancy unless the potential therapeutic benefits are deemed to significantly outweigh the possible risks.


Q: Can Kinito be split or crushed to make it easier to swallow?

A: Official instructions specify that the film-coated tablets must be swallowed whole with liquid and should not be split, crushed, or chewed.


Q: Does Kinito interact negatively with caffeine or energy drinks?

A: Caffeine is a known stimulant that affects the digestive tract. Consult a healthcare provider regarding the combined effects of Kinito with energy drinks or large amounts of caffeine, especially since official general advice for the underlying condition often includes minimizing dietary triggers.


Q: Does Kinito interact with common herbal remedies like St. John's Wort?

A: Kinito has warnings regarding use with agents that affect Serotonin levels. Herbal products such as St. John's Wort are known to influence Serotonin and combining them with Kinito may be associated with an increased potential for side effects.


Q: Does Kinito affect fertility in men or women?

A: Official safety data mentions the potential for hormonal effects, specifically increased prolactin levels (Hyperprolactinaemia) and male breast enlargement (Gynecomastia). These hormonal changes indicate a need for monitoring reproductive function.


Q: Why do some people need to adjust their Kinito dosage over time?

A: Dose adjustment or discontinuation may be necessary for specific populations, such as older adults or those with reduced kidney or liver function, due to altered drug metabolism and a higher potential for side effects.


Q: How do doctors monitor the effectiveness of Kinito?

A: In clinical practice, a doctor monitors the medicine's effectiveness primarily through the patient's report of symptom relief, such as reduced feelings of fullness or bloating. Clinical trials have measured effectiveness using patient questionnaires and studies of the gastric emptying rate.


Q: What is the difference between Kinito and similar medicines that treat the same condition?

A: Kinito is distinguished from other prokinetic agents by its dual mode of action: it blocks a dopamine receptor and inhibits the enzyme that breaks down a neurotransmitter (Acetylcholinesterase) in the gut. This results in a comprehensive motility-enhancing effect that is largely focused on the digestive system.


Q: Can Kinito cause changes in mood or sleep patterns?

A: Yes, official safety information lists changes in mood, such as irritability, and sleep disorders, such as insomnia, as Uncommon adverse effects associated with Kinito.

How should Kinito be stored and disposed of?

Storage Requirements for Kinito Tablets

Kinito (itopride hydrochloride) must be stored under conditions that maintain the tablet's stability. Official labeling generally requires the product to be stored at room temperature, which typically means a temperature not exceeding 25 C or 30 C.

  • The tablets must be protected from moisture and light and kept in a cool, dry place.
  • It is mandatory to store the medicine in its original container with the closure kept tightly closed when not in use.
  • As a prescription medication, Kinito must always be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Kinito must be disposed of according to local, regional, and national regulations. This product must not be thrown into household garbage or flushed down a drain unless specifically instructed by a regulatory authority, as the active substance is classified with warnings of being very toxic to aquatic life with long-lasting effects (H410). Patients should utilize authorized drug take-back programs where available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kinito found in:

A-Z Index: